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1. Increased bioburden in chronic 
diabetic foot ulcers (DFUs) 
causes a vicious circle of 
delayed healing. Biofilm, in 
particular, is a significant issue 
that needs to be addressed.
2. In the cases described, the 
addition of octenilin® to the 
patients’ DFU treatment 
regimen kick-started 
progression to healing 
3. Using a wound cleansing 
solution in addition to 
standard care resulted in 
improved infection control, 
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Diabetic foot ulcers (DFUs) are common and constitute a considerable burden 
for both patients and healthcare providers. Reducing the length of time to 
healing reduces the risk of infection and further morbidity. Biofilms delay 
healing, therefore, they should be treated with a biofilm-based wound care 
regimen consisting of debridement, topical agents (antimicrobials and antiseptics) 
and, if appropriate, systemic antibiotics (Cutting and Westgate, 2012). This 
case series focuses on the use of octenilin®, which contains a broad-spectrum 
antimicrobial, in the treatment of DFUs to address bioburden, prevent infection 
and progress healing. 
F oot ulcers are a common and disabling condition in people with diabetes, having a global prevalence of 6.3% (Zhang et 
al, 2017). Men are more likely than women to 
develop a diabetic foot ulcer (DFU) and people 
with type 2 diabetes are at greater risk than those 
with type 1 diabetes (Guest et al, 2015; Zhang et 
al, 2017). DFUs have a negative impact on patients’ 
quality of life, increase the risk of infection and 
amputation (Vileikyte, 2001; Ribu et al, 2007; 
Wukich and Raspovic, 2018), and constitute 
a considerable economic burden for healthcare 
providers (Diabetes UK, 2017). 
Each year, an estimated 2–2.5% of people with 
diabetes develop a DFU (Diabetes UK, 2017). In 
England in 2014–15, the estimated cost of foot 
ulceration and amputation was £1 billion, and this 
figure is expected to rise in the future (Kerr, 2017). 
It is, therefore, essential to identify and treat DFUs 
promptly to patient improve outcomes and reduce 
financial pressures on healthcare providers.
Chronic wounds, biofilms and 
infection
The most common risk factors for DFU 
formation are diabetic neuropathy and vascular 
disease (Wounds International, 2013), which slow 
healing and increase the risk that wounds will 
become chronic. Biofilms and infection can also 
impact the rate of healing.
The number of viable microorganisms 
present on a surface is known as the bioburden. 
Increased bioburden has been proposed as an 
important predictor of poor healing outcomes 
(Grice and Segre, 2012). Microorganisms 
(bacteria, fungi and protists) can change from 
single-celled free-moving forms to a structured 
community of cells known as a biofilm 
following attachment, growth and division 
phases. Mature biofilms are surrounded by a 
protective matrix, which makes them difficult 
to remove with antibiotics, antiseptics and 
disinfectants. At least 60% of chronic wounds 
have a biofilm (Phillips et al, 2010; Haycocks, 
2017). Their presence delays wound healing 
and they can act as a precursor to infection if 
not managed effectively (Phillips et al, 2010; 
Haycocks, 2017). 
Infection is the result of disease-causing 
microbes invading body tissues. Diabetic foot 
infection is a common complication and is 
associated with increased risk of hospitalisation 
and poor clinical outcomes, including increased 
risk of lower-extremity amputation, reduced 
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quality of life, and increased risk of mortality 
(Pickwell et al, 2015). It is, therefore, important 
to prevent infections or, if present, treat 
them promptly. 
Optimal management
If it is known or suspected that a biofilm is 
present, a biofilm-based wound care regimen 
should be implemented to reduce existing 
biofilms and prevent the formation of new 
ones. Management generally involves frequent 
debridement, the application of topical agents 
(including antimicrobials and antiseptics) and 
systemic antibiotics (if there is systemic infection) 
selected based on pathogen sensitivity (Cutting 
and Westgate, 2012). 
Debridement removes debris, necrotic tissue 
and reduces the bioburden. Various methods can 
be used and are considered effective in speeding 
up healing (Edwards and Stapley, 2010). 
Patients should be assessed for signs of 
infection. Wounds without evidence of soft 
tissue or bone infection do not require antibiotic 
therapy; however, when infection is present, 
a post-debridement specimen should be sent 
for aerobic and anaerobic culture. With acute 
infection, empiric antibiotics can be narrowly 
targeted at Gram-positive cocci (Lipsky et al, 
2012). Those with chronic, previously treated or 
severe infection or those at risk of infection with 
antibiotic-resistant strains often require broad-
spectrum antibiotics (Lipsky et al, 2012).  
Topical agents can be used to treat infection, 
as well as reduce or prevent biofilms, although 
not all agents do both. Antimicrobials can be 
incorporated into dressings, irrigation solutions 
or gels. Ideally, antimicrobial preparations 
should have a broad spectrum of activity, be fast-
acting, stable and non-cytotoxic (Apelqvist et al, 
2017). Silver and octenidine, for example, have 
demonstrated antimicrobial activity against a 
number of planktonic organisms known to form 
biofilms, including Pseudomonas aeruginosa and 
Staphylococcus aureus (Percival and McCarty, 
2015; Apelqvist et al, 2017). 
Silver-containing dressings have been shown to 
combat infection in chronic wounds and DFUs 
while minimising dressing-related pain (Richards 
and Chadwick, 2011). Antiseptic or antibiotic 
irrigation solutions, based on octenidine, 
polyhexanide or doxycycline, can be used with 
or without negative pressure wound therapy to 
treat chronic wounds and DFUs (Apelqvist et al, 
2017). In negative pressure wound therapy with 
instillation (NPWTi), solutions saturate the foam 
and bathe the wound, which is then cleansed for 
the recommended soak time before the f luid is 
removed and negative pressure restored. There is 
also evidence to favour NPWTi over conventional 
NPWT in DFUs as it promotes formation of 
granulation tissue and is the more cost-effective 
option (Gupta et al, 2016). 
Octenidine dihydrochloride: a broad-
spectrum antimicrobial 
Octenidine dihydrochloride is an antimicrobial 
with broad-spectrum efficacy and no known 
microbial resistance. It is a safe and effective 
agent that prevents bacterial growth (Cutting 
and Westgate, 2012). It is well tolerated, has no 
side effects and is not absorbed systemically. 
Octenidine also has deodorising properties, is 
active in as little as 60 seconds, and its biocidal 
activity lasts at least 48 hours.
octenilin® wound irrigation solution (schülke) 
is a colourless, alcohol-free solution containing 
octenidine, which has been designed to cleanse 
and moisturise chronic wounds and burns. 
octenilin® has been shown to inhibit the 
formation of biofilm material for up to 3 days 
(Cutting and Westgate, 2012). It can also be 
used to loosen encrusted dressings and cleanse 
hard-to-reach areas, such as small fissures and 
wound pockets (schülke, 2015; Haycocks, 
2017). octenilin® irrigation solution contains 
ethylhexylglycerin, which has surfactant, 
emollient, skin-conditioning and antimicrobial 
properties. Ethylhexylglycerin reduces the surface 
tension of aqueous solutions, enhancing its 
wetting behaviour (Cutting and Westgate, 2012). 
The presence of ethylhexylglycerin therefore 
optimises the spread of octenilin® irrigation 
solution into all wound fissures.
octenilin® wound gel is a hydrogel that can be 
used to reduce the risk of microbial colonisation 
of the wound. In a prospective randomised study 
of 61 patients with superficial skin graft donor 
site wounds, it significantly lowered microbial 
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colonisation compared to placebo (Eisenbeiss 
et al, 2012). In a prospective open-label study 
of 49 chronic venous leg ulcers, wound size 
reduction was significantly greater in patients 
treated with octenilin® wound gel or octenilin® 
wound gel plus modern phase-adapted dressings 
compared to those treated with modern dressings 
alone (Hämmerle and Strohal, 2016). The 
overall cost per patient was about 27% lower 
in the octenilin®-alone group due to earlier 
wound healing and the higher costs associated 
with phase-adapted dressings (Hämmerle and 
Strohal, 2016).  
octenisan® wash mitts (schülke) are soft 
octenidine-impregnated cloth wipes that can 
be used to decontaminate the skin around the 
wound to reduce risk of bacteria migrating 
into the wound before the application of a new 
dressing (schülke, 2015). The mitts should be 
used to decontaminate an area at least as large as 
the dressing. Dressings can be securely applied 
once the area is dry.
Case studies
Case study 1: patient with cellulitis, 
infection and osteomyelitis
This 49-year-old male patient had a history of 
type 2 diabetes, neuropathy, retinopathy and 
transient ischaemic attack. He has history of 
minor amputation of his left second toe. He 
presented with osteomyelitis of the second toe 
distal phalanx and ulceration to the apex of the 
right second toe. He attended urgent care as a 
result of cellulitis in his right second toe and was 
given oral f lucloxacillin 500 mg, to be taken four 
times daily. Five days later, he was referred to 
the community intravenous team as his cellulitis 
was advancing. At this time treatment with 
ceftriaxone 2g per day for 7 days, this treatment 
was extended to 6 weeks on confirmation of 
osteomyelitis, and povidone iodine-impregnated 
gauze was commenced. The dressing was changed 
twice weekly. 
He was referred to podiatry from the 
community intravenous team and seen within 
1 working day. On review by podiatry, the patient 
had an ulcer on the apex of his right second toe 
covering a 5 cm2 area (2 cm × 2.5 cm). Bacterial 
infection was diagnosed based on the clinical 
symptoms of redness, swelling, heat and cellulitis 
(Lipsky et al, 2012) and the wound bed consisted 
of bone, slough and granulation tissue (Figure 1a). 
Assessment of the ulcer gave a Site, Ischaemic, 
Neuropathy, Bacterial infection and Depth 
(SINBAD; Ince, 2008) score of four out of six 
— an indication for poor healing — and a Texas 
grade (Lavery, 1996) of B3 (a wound penetrating 
to bone or joint with infection). A probe-to-
bone test suggested the presence of osteomyelitis 
(Lipsky et al, 2012). The patient was diagnosed 
with neuropathic DFU with soft tissue infection 
and suspected osteomyelitis. Intravenous antibiotic 
therapy was prescribed to treat the infection. 
Following sharp debridement, he was started 
on a treatment regimen including cleansing 
the wound bed with octenisan® wash mitt 
and octenilin® irrigation solution, followed 
by application of a foam dressing. After sharp 
debridement, the wound was cleansed with the 
octenisan® wash mitt. The wound was then 
flushed with octenilin® irrigation solution and 
octenilin®-soaked gauze swabs were placed over 
and, where possible, in to the wound bed for 
5 minutes. This process was conducted at the 
weekly dressing review with podiatry for 2 weeks. 
During this time period, the patient was also on 
the once daily treatment of ceftriaxone 2g.
The right distal phalanx was loose a week after 
the patient’s podiatry review, so the majority of the 
bone was removed and sent to microbiology. The 
podiatrist continued to use octenilin® irrigation 
solution and octenisan® wash mitt as part of the 
patient’s treatment regimen. Oral metronidazole Figure 1. Case 1, patient with cellulitis, infection and osteomyelitis (a) 17.05.18; (b) 31.05.18.
(a) (b)
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400mg three times per day was introduced 
following microbiology test results, which showed 
presence of anaerobic bacteria. Seven days later, the 
wound measured 1 cm × 1.5 cm, 85% of the wound 
bed comprised granulation tissue, and there was 
evidence of epithelisation (Figure 1b). The ulcer 
had a SINBAD score of two and a Texas grade of 
A1. At this time, the octenilin® irrigation solution 
was discontinued.
Case study 2: older patient with chronic 
kidney disease and DFU 
An 85-year-old male with type 2 diabetes, 
stage 3 chronic kidney disease and peripheral 
arterial disease presented with ulceration of the 
right lateral fifth metatarsophalangeal joint. The 
patient’s peripheral arterial disease had recently 
been assessed by duplex ultrasound, which had 
revealed vessel disease distal to the popliteal fossa, 
and he was awaiting a review of his duplex results 
and a treatment plan. The metatarsophalangeal 
joint ulcer initially measured 0.2 cm × 0.4 cm and 
assessment revealed monophasic pulse signals and 
active ulceration. The patient was referred to the 
vascular service. Infection was present 17 days 
later; as a result, flucloxacillin 500 mg four times 
per day for 7 days was prescribed. He was treated 
topically with dialkylcarbamoylchloride (DACC)-
coated gauze. At this time, the ulcer measured 
0.8 cm × 0.6 cm and was continuing to deteriorate 
(Figure 2a). 
There was no soft tissue infection present 
6.5 weeks later but the presence of biofilm was 
suspected due to the chronic nature of the wound. 
The wound bed consisted of 95% slough and 5% 
granulation, and had extended to 1 cm × 1 cm 
(Figures 2b; 2c). On assessment, the ulcer was 
classed as Texas grade C1 and had a SINBAD 
score of two. Post-debridement, octenisan® 
wash mitt was used to topically clean debris. 
octenilin® wound gel was also used to reduce 
the risk of infection and avoid the possibility of 
prolonged antibiotics use in this patient due to 
his advanced age and kidney disease. The wound 
was dressed with a non-adhesive foam dressing 
throughout treatment.
The wound was similar in size and appearance 
when the patient attended the service 8 days 
later. Three weeks after starting treatment with 
octenilin® wound gel, however, there was a 
noticeable improvement in the wound bed, which 
consisted of 60% granulation and 40% slough. 
There was evidence of epithelialisation and the 
ulcer had reduced in size by 25% (Figure 2d), as 
such, octenilin® wound gel was discontinued.
Case study 3: diabetic foot with severe 
infection and multiple DFUs
This 64-year-old male patient initially presented 
with a 4-day history of redness and swelling 
of the foot to the emergency room. He had 
chronic alcoholism and was diagnosed with 
type 2 diabetes a year ago, but was not taking 
any medication. Erythema and oedema of the left 
instep were present. The patient was diagnosed 
with erysipelas and Tinea pedis, and discharged 
on oral flucloxacillin. His temperature was 
slightly raised and he was tachycardic (105 beats 
per minute) 2 days later. The inflammation 
had extended towards the lower leg and there 
was a spontaneously draining abscess on his left 
Figure 2. Case 2, older patient with chronic kidney disease and diabetic foot ulcers (top left 
and clockwise). (a) 19.03.18; (b,c) 02.05.18; (d) 23.05.18
(a) (b)
(c) (d)
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instep. The patient’s antibiotic was changed 
to amoxicillin with clavulanic acid and he 
was discharged.
Five days later, a GP sent the patient to the 
emergency room with symptoms of confusion, 
fever (38°C), tachycardia (101 beats per 
minute), leukocytosis, high C-reactive protein 
and hyperglycaemia. There were ulcers on 
the first metatarsal, on the base of the third, 
fourth and fifth toes, and on the anterior face 
of the tibial–tarsal transition (Figure 3a). The 
tendons were exposed and there were several 
abscesses containing purulent, foul-smelling 
exudate. The patient was admitted to hospital, 
a biopsy tissue collection for bacteriologic 
study ordered, and linezolid 600 mg IV every 
12 hours was commenced. He was referred to 
the multidisciplinary leg ulcer and diabetic foot 
team. Although his HbA1c was high (10.7%), the 
patient’s vascular status was considered normal for 
his age. The wound was considered a condition of 
neuropathic diabetic foot complicated by a severe 
soft tissue infection. Initial treatment involved 
aggressive surgical debridement with drainage 
of the abscesses, followed by debridement using 
mechanical hydrodissection technique. NPWTi 
using intermittent instillation of octenilin® 
irrigation solution (125 mmHg, 10 minutes dwell 
time every 8 hours) were instigated and the 
patient’s dressings changed every 3 days. Serratia 
marcescens, methicillin-sensitive Staphylococus 
aureus and Enterobacter hormaechei were present, 
so he was started on clindamycin and piperacillin 
plus tazobactam.
Nine days later there was a marked 
improvement; the ulcers were shallower and 
the wound beds contained granulation tissue 
(Figure 3b). The ulcers were packed with sterile 
swabs moistened with octiset®, which was changed 
every 2 days. After 3 weeks (Figure 3c), the patient 
was discharged to primary care, where a dressing 
soaked in octenilin® solution was applied to his 
foot three times a week. The wounds continued 
to improve (Figure 3d), and had fully healed 
12 weeks after local treatment with octenilin® 
irrigation solution was initiated (Figure 3e). 
Figure 3. Case 3, Diabetic foot with severe infection and multiple diabetic foot ulcers (top left and clockwise). (a) initial assessment; (b) Six days;  
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Summary 
The addition of octenilin® to the patients’ DFU 
treatment regimen kick-started progression to 
healing in the cases described. Its broad-spectrum 
antimicrobial action makes it suitable for use 
where biofilm is suspected, when the organisms 
colonising a biofilm are unknown (as in case 2), 
and in situations when multiple organisms are 
present (as in case 3), some of which may be 
resistant to antibiotics. octenilin® is also useful in 
the prevention of infection when the use of long-
term systemic antibiotics is undesirable, such as 
in case 2 where the elderly patient had chronic 
kidney disease. 
Appropriate classification of patients with 
ulcers is important when selecting treatment and 
monitoring progress to healing from baseline. 
The University of Texas system is both f lexible 
and descriptive and the SINBAD score is useful 
in predicting ulcer outcome (Ince et al, 2008). 
DFU classification provided a clear guide to the 
progression of healing in case 1, for example, with 
the SINBAD score improving from four to two 
and the Texas grade from B3 to A1. 
Conclusion
In the case studies described, the addition of 
octenilin®, with its broad-spectrum antimicrobial 
action, to the patients’ treatment regimens 
contributed to the DFUs progressing to healing. 
Used in conjunction with debridement and 
systemic antibiotics as part of biofilm-based 
wound care, octenilin® irrigation solution, 
octenilin® wound gel and octenisan® wash mitts 
are capable of managing bioburden in chronic 
wounds and aiding healing.  n
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